FOSCAVIR^® (FOSCARNET SODIUM)

Clinigen supplies Foscavir^® across 43 global markets.

Foscavir^® is licensed to treat:

Cytomegalovirus (CMV) retinitis in HIV patients
Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients

How does it work?

Foscavir^® selectively inhibits virus-specific DNA polymerase at the pyrophosphate binding site to produce an antiviral effect
Since it doesn’t require activation by kinases, it’s active in-vitro against HSV TK deficient mutants and CMV UL97 mutants
HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to Foscavir^®

Where is Foscavir^® licensed?